Anemia hemolítica autoimune na doença de Castleman multicêntrica: relato de caso
Autoimmune hemolytic anemia in multicentric Castleman's disease: case report
Marcos Tadeu Nolasco da-Silva; Katariny Parreira de Oliveira Alves; Izilda Aparecida Cardinalli; Amanda Avesani Cavotto Furlan; Priscila Machado Fernandes
Resumo
A doença de Castleman é um distúrbio linfoproliferativo raro, podendo se manifestar sob a forma de massas localizadas ou como doença multicêntrica. A doença de Castleman multicêntrica é caracterizada por adenopatias generalizadas, visceromegalias, manifestações autoimunes e infecções recorrentes. Este artigo apresenta o relato de caso de anemia hemolítica autoimune por anticorpos quentes em paciente com doença de Castleman multicêntrica. Resposta eficaz foi obtida com uso de corticoterapia sistêmica e tocilizumabe.
Palavras-chave
Abstract
Castleman disease is a rare lymphoproliferative disorder that can manifest as localized masses or as multicentric disease. Multicentric Castleman disease is characterized by generalized adenopathies, visceromegaly, autoimmune manifestations, and recurrent infections. This article presents the case report of a patient with multicentric Castleman's disease and autoimmune hemolytic anemia by warm antibodies. Effective response was obtained with systemic corticotherapy and tocilizumab.
Keywords
Referências
1. Castleman B, Towne VW. Case records of the Massachusetts General Hospital: Case No. 40231. N Engl J Med. 1954;250(23):1001-5.
2. Izuchukwu IS, Tourbaf K, Mahoney MC. An unusual presentation of Castleman’s disease: a case report. BMC Infect Dis. 2003;3:20.
3. Beck JT, Hsu SM, Wijdenes J, Bataille R, Klein B, Vesole D, et al. Brief report: alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602-5.
4. Wu S, Lim MS, Jaffe ES. Pathology of Castleman Disease. Hematol Oncol Clin N Am. 2018;32:37-52.
5. Ioachim HL, Medeiros LJ. Ioachim´s lymph node pathology. Philadelphia: Wolters Kluwer/Lippincott Williams&Wilkins; 2009. p. 228-37. ISBN/ISSN: 9780781775960.
6. Saeed-Abdul-Rahman I, Al-Amri AM. Castleman disease. Korean J Hematol. 2012;47(3):163-77.
7. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-57.
8. Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood. 2014;123:2924-33.
9. Fajgenbaum DC, Uldrick TS, Bagg A, Frank D, Wu D, Srkalovic G, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. Blood. 2017;129(12):1646-57.
10. Liberato NL, Bollati P, Chiofalo F, Filipponi M, Poli M. Autoimmune hemolytic anemia in multicentric Castleman’s disease. Haematologica. 1996;81:40-3.
11. Ocio EM, Sanchez-Guijo FM, Diez-Campelo M, Castilla C, Blanco OJ, Caballero D, et al. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena. Am J Hematol. 2005;78(4):302-5.
12. Tajima K, Yamamoto H, Suzuki I, Kato Y, Hatano K, Takahashi S, et al. Autoimmune hemolytic anemia with warm-reactive immunoglobulin M antibody in multicentric Castleman disease. Ann Hematol. 2013;92(6):849-51.
13. Yuzuriha A, Saitoh T, Koiso H, Mitsui T, Uchiumi H, Yokohama A, et al. Successful treatment of autoimmune hemolytic anemia associated with multicentric Castleman disease by anti-interleukin-6 receptor antibody (tocilizumab) therapy. Acta Haematol. 2011;126(3):147‑50.
14. Hisatake J, Ishiyama T, Akimoto Y, Matsuda I, Hino K, Tomoyasu S, et al. [Autoimmune hemolytic anemia associated with multicentric Castleman’s disease with a 28-year history]. Rinsho Ketsueki. 1994;35(8):768-73.
15. Tabata S, Higuchi T, Tatsukawa S, Narimatsu K, Takeo H, Matsukuma S, et al. Idiopathic Multicentric Castleman Disease with Autoimmune Hemolytic Anemia and Production of Anti-drug Antibody against Tocilizumab. Intern Med. 2019;58(22):3313-8.
16. Yoshizaki K, Murayama S, Ito H, Koga T. The Role of Interleukin-6 in Castleman Disease. Hematol Oncol Clin North Am. 2018;32(1):23‑36.
17. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74(4):1360-7.
18. Yoshizaki K, Matsuda T, Nishimoto N, Kuritani T, Taeho L, Aozasa K, et al. Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood. 1989;74(4):1360-7. PMID: 2788466.
19. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman’s disease by humanized antiinterleukin-6 receptor antibody therapy. Blood. 2000;95(1):56-61.
20. Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106(8):2627-32.
21. Caligaris-Cappio F, Bertero MT, Bergui L. Autoimmunity, autoimmune diseases and lymphoproliferative disorders. Haematologica. 1994;79(6):487-92.
22. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood. 1993;81:2475‑87.
23. Liu AY, Nabel CS, Finkelman BS, Ruth JR, Kurzrock R, van Rhee F, et al. Idiopathic multicentric Castleman’s disease: a systematic literature review. Lancet Haematol. 2016;3(4):e163-75.
24. Featherstone T, Bayliss AP, Ewen SWB, Brunt PW, Dawson AA. Obscure anemia and hepatic dysfunction in Castleman’s disease. Gut. 1990;31:834-7.
25. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for the development of collagen-induced arthritis. J Exp Med. 1998;187(4):461-8.
26. van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018;132(20):2115-24.
27. Kamesaki T. [Recent progress of diagnosis and treatment for immune-mediated hematological diseases. Topics: III. Diagnosis and treatment; 2. Autoimmune hemolytic anemia]. Nihon Naika Gakkai Zasshi. 2014;103(7):1599-608.
28. Xu L, Zhang T, Liu Z, Li Q, Xu Z, Ren T. Critical role of Th17 cells in development of autoimmune hemolytic anemia. Exp Hematol. 2012;40:994-1004.
29. Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance. Eur J Immunol. 2010;40:1830-5.
30. Kunitomi A, Konaka Y, Yagita M, Nishimoto N, Kishimoto T, Takatsuki K. Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia. Int J Hematol. 2004;80:246-9.
31. Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, et al. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clin Cancer Res. 2015;21(19):4294-304.
Submetido em:
18/10/2021
Aceito em:
13/11/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email